Ladies and gentlemen, welcome to the Dexcom second quarter 2026 earnings release conference call. My name is Abby and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. During the question and answer session, if you have a question, please press star one on your touchtone phone. As a reminder, the conference is being recorded. I will now turn the call over to Sean Christensen, Senior Vice President of Finance and Investor Relations. Mr. Christensen, you may begin. Thank you, operator, welcome to Dexcom's second quarter 2026 earnings call. Our agenda begins with Jake Leach, Dexcom's President and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer. Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question each so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our second quarter 2026 performance on the Dexcom investor relations website on the Events and Presentations page. With that, let us review our safe harbor statement. Some statements on today's call may constitute forward-looking statements. These statements reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, operating plans, and performance. These statements are made as of the date hereof based on information currently available to Dexcom, are subject to various risks and uncertainties that could cause actual results to differ materially. For discussion of these risks, please see Dexcom's annual report on Form 10-K, most recent quarterly report on Form 10-Q, and other filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update any forward-looking statements or to conform any forward-looking statement to actual results. Additionally, during the call, we will discuss certain non-GAAP financial measures. Unless otherwise noted, all financial measures discussed on this call are presented on a non-GAAP basis. Non-GAAP measures should not be considered in isolation or as a substitute for or superior to GAAP results. Please refer to the tables in our earnings release and the slides accompanying our second quarter 2026 earnings call for reconciliations to the most directly comparable GAAP measure. Now, I will turn it over to Jake. Thank you, Sean, and thank you everyone for joining us. Today, we reported second quarter revenue growth of 13% compared to the second quarter of 2025, and organic revenue growth of 12%. We carried forward solid demand from the first quarter for Dexcom CGM globally as we benefited from broader access and share gains across several core markets as well as patient categories. The second quarter was also marked by solid execution across the business. This included multiple product launches, strong margin execution, and excellent product performance in the field. In addition, global new customer starts remained in line with our previous record from last quarter, including a sequential uptick in new customer starts in the U.S. During the quarter, we had the opportunity to connect with many of you at our 2026 Investor Day, which we hosted at our Arizona manufacturing facility. Since I stepped into the role of CEO, you've heard me reiterate my three priorities for Dexcom's next phase of growth. One, be the premier glucose sensing solution for all. Second, set the standard for customer experience. Third, expand international market share. This event provided an opportunity to explore each of these topics in much greater detail. During the day, we shared updates on our product roadmap, reimbursement plans, international strategy, and future market opportunities. We also laid out our new five-year financial targets and capital allocation plans, which included a $1 billion share repurchase authorization to be executed in 2026. A key part of our presentation was detailing the pathway to full coverage for the 25 million people in the U.S. with type 2 diabetes not using insulin. In fact, we have an organizational initiative called The Road to 100, which represents our efforts to achieve coverage for all people with diabetes. While it's only been two months since our Investor Day, we've recently took an important step forward in advancing that opportunity. As many of you know, at this year's American Diabetes Association Scientific Sessions, we provided a full readout of CONNECT, our randomized controlled trial for people with type 2 diabetes who are not on insulin. For background, CONNECT enrolled nearly 300 participants across 22 primary care sites in the U.S. and was designed to reflect the wide spectrum of people with type 2 diabetes. This included individuals across the full range of type 2 medication plans to ensure these results were reflective of real-world care, and we could not have been happier with the results. Over the six-month study period, we saw a 1.6% A1C improvement for the Dexcom CGM group, which equated to a 0.9% difference in A1C between the CGM arm and the control group. To put this in perspective, these results are even better than what we saw in our landmark DIaMonD and MOBILE studies, which ultimately helped shift standards of care and led to full coverage for anyone using insulin. Beyond the strong headline results, several additional outcomes stood out in the CONNECT trial. First, the Dexcom CGM arm spent over five more hours per day in normal glucose range compared to the control group. Importantly, these improvements began within the first week of using Dexcom and were sustained over the 26-week study. These were individuals who've had diabetes for 10+ years on average, and Dexcom immediately gave them a path to better glucose control. Second, this real-time feedback led to very high engagement throughout the trial. Over the 26-week study, median CGM usage was 97%, which is even higher than what we have seen in some AID trials. Finally, from a medication perspective, the largest relative improvement in A1C was within the cohort using only GLP-1 therapies. This data only further reinforced the complementary relationship between CGM and incretin therapy. The results demonstrated in CONNECT translate to meaningful health outcomes and economic savings, and we are already seeing this recognized by commercial payers. As an example, in collaboration with CVS Health, we published a real-world evidence study for non-insulin type 2 customers. Over a three-year period, the study showed a 66% reduction in diabetes-related hospitalizations after the initiation of CGM, and nearly 50% reduction in microvascular complications. These tangible near-term cost savings are a key reason why we've seen commercial coverage build so quickly. As we mentioned in our Q1 call, as of this summer, we now have coverage for all people with diabetes across the four largest commercial PBMs. This represents reimbursement for more than seven million people with type 2 diabetes who are not on insulin. While this is a great start, we have stated previously, we won't be satisfied until we have broad global coverage for all people who can benefit from Dexcom CGM, including 25 million type 2 non-insulin customers in the U.S. The CONNECT readout adds level A evidence to the already substantial body of real-world type 2 data and our momentum with commercial payers. Historically, this level of evidence has carried outsized influence in both shaping clinical practice and driving coverage forward, both in the U.S. and across international markets. We're now working with advocacy groups and KOLs across the world to help educate the market on these outcomes. We've also submitted the CONNECT data for publication and provided the evidence to CMS in support of the non-insulin coverage expansion. We believe these results only strengthen the case for reimbursement, and with roughly half of the type 2 non-insulin population being of Medicare age, this decision has the potential to completely reshape diabetes care in the U.S. The administration is already demonstrating their commitment to reducing the burden of chronic disease and expanding access to new technologies. Along those lines, we are excited to see the FDA's announcement of Dexcom as the first company chosen to participate in the TEMPO Digital Device Pilot. As I shared at Investor Day, we believe that Dexcom's opportunity goes beyond diabetes care and into diabetes prevention. We have 115 million Americans with prediabetes, but only a fraction of them are aware. Under TEMPO, we will have the ability to demonstrate Dexcom's ability to screen for prediabetes with Dexcom CGM and drive people to better metabolic health. As we continue to expand the horizons of CGM access and metabolic health, we are driving exciting product enhancements that meet the needs of our customers. This includes our fully redesigned Stelo app, which launched broadly last week. As you saw at Investor Day, this new interface offers a more consumer-friendly feel, new AI-driven insights, and enhanced food logging capabilities. This Stelo update also creates the foundation from which our G Series app will evolve, providing greater personalization and additional functionality for all customers. More broadly, our technology roadmap remains focused on delivering innovations that can improve outcomes and the user experience. A great example of this is Dexcom Smart Basal. As a reminder, Smart Basal is a personalized dosing module to help simplify and optimize basal insulin management for both customers and physicians. We developed this technology to address a significant unmet need, as more than 70% of patients on basal insulin fail to achieve target A1C levels after a year of therapy, often due to the challenges associated with insulin titration. We currently have our pilot program of Smart Basal underway with several key KOLs, and the feedback has been great. In fact, across these practices, Smart Basal has helped customers reach an optimal basal dose in only three weeks on average, which is a process that typically takes 12 weeks or longer in routine care. These results validate our belief that Smart Basal has the potential to become the new standard of care for basal insulin management. During the quarter, we also continued to advance the rollout of our Dexcom G7 15-day system. With the recent integration availability for Tandem pump users, including Mobi, our G7 15-day system is now accessible for all adult G7 customers in the U.S. We're very encouraged by the response we've seen since launch. With great feedback on the new algorithm, updated patch, extended wear time, and enhanced customer service. Importantly, these improvements are translating into stronger customer satisfaction, with G7 Net Promoter Scores increasing in each of the last three quarters. Based on this positive customer feedback, strong adoption trends, and growing interest across the market, we remain on track to convert nearly 50% of our U.S. customer base to the Dexcom G7 15-day system by year-end. At Investor Day, we also discussed our plans to extend this 15-day experience across our international markets. We recently completed an important step on that journey as Health Canada became the first international regulator to clear Dexcom G7 15-day. We look forward to bringing Dexcom G7 15-day to Canada in the second half of 2026 and to the rest of our international markets as quickly as possible. To close, it was great to connect with many of you in Arizona to share our vision for Dexcom's next chapter of growth and to support that vision with a strong quarter of execution. As we discussed at the event, we see a significant opportunity to help millions more people globally. In fact, through our ongoing advocacy work, access efforts, market expansion, and product development, we believe we can exit our LRP with an even larger market opportunity than we have today, and we plan to execute on that growth vision with one of the more compelling cash flow and margin profiles in the industry. As you can tell from today's updates, we are wasting no time making this vision a reality. With that, I'll turn it over to Jereme. Thank you, Jake. As a reminder, unless otherwise noted, the financial metrics presented today will be discussed on a non-GAAP basis. Reconciliations to GAAP can be found in today's earnings release as well as the slide deck on our IR website. For the second quarter of 2026, we reported worldwide revenue of $1.31 billion compared to $1.16 billion for the second quarter of 2025, representing growth of 13% on a reported basis and 12% on an organic basis. As a reminder, our definition of organic revenue excludes the impact of foreign exchange in addition to non-CGM revenue acquired or divested in the trailing 12 months. U.S. revenue totaled $933 million for the second quarter compared to $841 million in the second quarter of 2025, representing an increase of 11%. We continue to see strong new patient performance and share capture in the U.S. market with good sequential momentum driven by solid execution in the field. International revenue grew 19%, totaling $375 million in the second quarter. International organic revenue growth was 16% for the second quarter. As we've seen over the past several quarters, some of our strongest performances came from markets where access has recently expanded, such as France and Canada. This is consistent with the international access strategy we outlined at Investor Day, as reimbursement wins often allow us to drive growth and market share over time. We also continued to expand our international product portfolio during the quarter with the launch of Dexcom Flex in Germany. Dexcom Flex is our newest Dexcom G7 15-day sensor designed to address Type 2 basal in the Type 2 non-insulin markets in select geographies. We're excited to further roll out this product as Type 2 reimbursement continues to build. Our second quarter gross profit was $838.5 million, or 64.1% of revenue, compared to 60.1% of revenue in the second quarter of 2025. This was another great quarter for gross margin performance, with margins improving approximately 400 basis points compared to last year. This improvement was driven by continued manufacturing efficiencies in quality management and a benefit from the initial customer switchover to Dexcom G7 15-Day. As Jake mentioned, our execution has been excellent across our operations and supply chain. This included a return to more optimized shipping patterns, which helped us manage the fuel price environment in Q2. Operating expenses were $510.2 million for Q2 of 2026, compared to $474.1 million in Q2 of 2025. Operating income was $328.3 million, or 25.1% of revenue in the second quarter of 2026, compared to $221.8 million, or 19.2% of revenue in the same quarter of 2025. Once again, we delivered nice operating expense leverage during the quarter, even as we expanded our investment in Ireland to prepare for commercial production later this year. This quarter was another great representation of ongoing cost discipline across our organization, which is driving margin performance and funding growth opportunities across the business. Adjusted EBITDA was $421.3 million, or 32.2% of revenue for the second quarter, compared to $327.6 million, or 28.3% of revenue for the second quarter of 2025. Net income for the second quarter was $269.1 million or $0.70 per share, representing 46% growth over the second quarter of 2025. We remain in a great financial position, closing the quarter with approximately $1.9 billion of cash and cash equivalents. Our cash flow generation continues to be a key differentiator as we delivered more than $600 million in free cash flow in the first half of the year. This was more than double our first half free cash flow levels from 2025. As Jake mentioned, at Investor Day, we announced a commitment to repurchase $1 billion of stock in 2026. Following the event, we quickly started executing that plan and repurchased approximately $600 million in the second quarter. During the day, we also shared broader framework for our capital allocation decisions, which includes an ongoing assessment of tuck-in M&A and where to invest for future production capacity. As we discussed, one area of particular interest is in transactions that have the potential to accelerate our technology pipeline. In line with that framework, we completed the acquisition of Nutrisense during the second quarter. Nutrisense has developed an innovative platform built on CGM data with a focus on delivering nutrition-focused insights. We believe this integration has the potential to enhance our customer experience and provide new personalized insights. Turning to guidance, we are raising the midpoint of our guidance with an updated range of $5.18 billion- $5.25 billion, representing growth of 11%-13% for the year. This updated revenue guidance reflects stronger organic growth expectations offset by recent movement in foreign exchange rates, which we expect to have about a $15 million impact to international revenue in the second half of the year relative to our prior guidance. Importantly, excluding the impact of foreign exchange, our updated guidance implies an increase in organic growth by more than 50 basis points at the midpoint compared to our prior guide. For margins, we are raising our full-year non-GAAP gross profit margin guidance to approximately 64%. We are also increasing our non-GAAP operating profit margin guidance to a range of 23.5%-24% and adjusted EBITDA margin guidance to a range of 31.5%-32%. With that, we can open up the call for Q&A. Sean? Thank you, Jereme. As a reminder, we ask our audience to limit themselves to only one question at this time and then re-enter the queue if necessary. Operator, please provide the Q&A instructions. Thank you. We'll now begin the question and answer session. If you have a question, please press star one on your touch-tone phone. If you wish to be removed from the queue, please press star one a second time. If you're using a speakerphone, you may need to pick up the handset first before pressing the numbers. Once again, if you have a question, it is star one on your touch-tone phone. Our first question comes from the line of Travis Steed with Bank of America. Your line is open. Hey, congrats on a good quarter. Maybe I'll ask about this U.S. CGM growth for Dexcom and also the market. It was nice to see the quarter-over-quarter uptick in new patient starts. The market for CGM in the U.S. kind of hanging around the 10% line. Just the confidence you're seeing in that sustainability of double-digit growth and how to think about some of the new products and expanding coverage, as those hit later this year and what you're assuming for Nutrisense in the second half on the guidance. Thank you. Yeah, thanks, Travis. I'll take that one. It was another robust quarter of new patient starts, and it was nice to see the sequential uptick in the U.S., and it was pretty broad-based across all of our patient segments. As we mentioned the call, we saw some share taking across those. When you take a step back and you look at the U.S. market today, there's approximately 9 million people in the United States that have coverage for CGM but aren't yet using it. We do feel that there's robust growth still there before we talk about any expansion in coverage. Happy with the patient adds. We're going to continue to drive and push so that everyone that can benefit from this technology gets it. As you mentioned, CMS expansion is something that we've targeted for mid-next year, is when we believe that coverage will come into place. That obviously gives us a pretty significant runway for future growth. Nutrisense, as you mentioned, is one of the acquisitions that we've made, and it really is focused on driving better insights and more value from our product. It was a really exciting technology that the team developed. We've been partners with Nutrisense for quite a while, and as we continued to work with them, we saw just the benefits that technology could bring to the users. The engagement scores early on are really high because of the personalized nutrition coaching based on CGM that we see with that technology. We're continuing to work with it and integrate it into our product portfolio, and we're excited to see where it can drive us. To your question on guidance, Travis, most of the revenue that ran through Nutrisense both was actually the pass through the CGM. That's always been in our run rate, and that'll continue into our run rate. I would say that any other contribution, say, on the top line, you can count the millions for the year on one hand, so it's truly immaterial in terms of the impact to the organization. In terms of the P&L, we're assuming the P&L associated with that into that guidance, into the range of our guidance. All of that is really contemplated in there. Maybe most importantly, I think the big takeaway here is the run rate that Nutrisense had, most of it was already sell-on revenue, and so it continues to remain. It doesn't really change the organic growth profile. Our next question comes from the line of Robbie Marcus with JP Morgan. Your line is open. Robbie, your line is open. Please check your mute button. Great. Sorry, just jumping back and forth. Appreciate it. Wanted to ask on CONNECT and the reception amongst doctors following ADA and how you're thinking about how this data set and hopefully the eventual Medicare non-intensive reimbursement might help stimulate and advance adoption in type 2 non-intensives. What's been the feedback, and do you think this trial was a door that could open and help drive adoption once reimbursement comes? Thanks. Thanks, Robbie. Absolutely. The results from the CONNECT trial, both in terms of the A1C reduction across the broad spectrum of type 2 users on all kinds of different medication plans, as well as the engagement with the technology. It's interesting. The engagement is very, very high in this population. If you look at it compared to some of the older studies, one thing that I'll always remember is that the technology's improved pretty substantially over time. I think what we've seen in this study is not only the benefit to these users and their engagement with the product, but also the quality of the product experience. If you think about some of the earlier studies, those started back even on G4. Now G7, with all the enhancements we've made to both ease of use, have really driven the capability for these folks to use this product full time. As I mentioned, 97% utilization. I think that really resonates with providers, because if they're writing the prescription for the product and they want their patient to get it, they want them to use it. I think this trial's a great proof point in how this product will be used in this population. We saw it in our registry data. We saw great utilization for those that already are using it. But in this trial, I think that stands out substantially, as well as the improvement in A1C. Right now, we're working with that data. We've submitted it. It's in late stage review for publication. We'll continue to take that data around the world to drive reimbursement. This is the type of trial that previously has driven pretty significant expansions. Our previous trial is obviously for insulin users. This one now for the broad segment of type 2. We do feel that is a very important part. The evidence was strong before the CONNECT trial results were available, but now that they're available, it just really reinforces the benefit that this technology has in the broad base of diabetes. Our next question comes from the line of Matt Taylor with Jefferies. Your line is open. Hi. Thank you for taking the question. I just wanted to follow up on CONNECT and non-insulin type 2. You talked about having submitted the data package to CMS as well. Could you give us any update, if there is one, on the timeline that you might expect for coverage? You said mid 2027 previously. Is that still your base case, or could it potentially be sooner with the progress that you've made? Yeah, we did submit the CONNECT data to CMS. Again, it adds to that pretty substantial body of evidence that was already there. No change in our assumptions around the coverage decision. We do expect to hear back from CMS on that decision before the end of this year. In our plans right now, we've got it taking effect in the middle of 2027. That being said, I do believe that CONNECT is a pretty powerful data set that, not only for CMS but for the world, will continue to advance reimbursement for this population. Our next question comes from the line of Larry Biegelsen with Wells Fargo. Your line is open. Hi. This is Gursimran on for Larry. Thanks for taking the questions, and congrats on a good quarter here. I'll just ask mine about the pilot program with the FDA, TEMPO. What does TEMPO mean for type 2 non-insulin and pre-diabetes coverage exactly? Can you just elaborate on the kind of evidence development in the TEMPO program for those two indications, and when you could potentially have a pre-diabetes label? Then, is there any near-term revenue benefit from CMS coverage and any kind of read-through to just broader type 2 non-insulin CMS coverage from it being mentioned alongside the TEMPO program as well? Yeah. Thanks, Gursimran. TEMPO, it's an innovative regulatory framework introduced by the FDA. It's really around access to technology for patients. It aligns the target areas for the TEMPO framework is around the areas that were identified by the ACCESS program from CMS, which are early stage cardiometabolic conditions and cardiometabolic conditions. We're talking pre-diabetes and diabetes obviously squarely fit into those. It's really around allowing the participants of TEMPO to release into the market digital technologies under, basically, it's like an enforcement discretion. Basically, what it means for Dexcom is it allows us to innovate more quickly on our glucose health program, as well as some screening techniques that we're looking at using CGM to screen for pre-diabetes as well as diabetes because of the pretty significant lack of awareness of pre-diabetes diagnosis. We believe that CGM is a really powerful technology to help intervene more earlier in the progression of disease. TEMPO is not really specific to a coverage. It is really more a framework to get technology in the hands of users. The ACCESS program does add additional payments into the system for Medicare beneficiaries, so obviously a technology that under TEMPO can help there. It is not connected at all to the kind of general CMS decision for a broad coverage for type 2. It is really more specific to the TEMPO and ACCESS programs. Our next question comes from the line of Matt O'Brien with Piper Sandler. Your line is open. Great. Thanks. This is Ana on for Matt. Thanks for taking our question here. I wanted to ask on Dexcom G7 15-day, you mentioned the 50% conversion by the end of the year in the U.S. Just wanted to know if there was any color you could provide on where conversion to Dexcom G7 15-day sits exiting Q2, and how you are thinking about the accretive margin impact from that big shift for the rest of the year, if that is sort of showing up in line with your expectations or anything to note there. Thanks. Sure. I can take that question. The transition is occurring essentially in line with expectations. If you think about all the assumptions as we were going into the year, obviously we really launched it in earnest in full starting in January. We did a little bit of an early release in the DME space in the back quarter of last year. It went into retail at the beginning of this year. If you think about a line drawing through, there is obviously folks that have adopted it over the course first half of the year. One of the big gaining items was, of course, thinking about its integration with Tandem and Mobi, and Jake alluded to it earlier. That is now gone into full launch here as we move into the back half of the year. Our expectations were you'd continue to see it ramp up, especially as all of the AID integrations took place You're seeing the Tandem coming in now, and it's already connected to Beta Bionics and Insulet. We're making great progress. It's about in line with expectations, you're seeing it start to contribute a little bit more here in the second quarter. The expectation is it starts to contribute more into the third quarter and the fourth quarter, as your base continues to move over and as that starts to represent recurring purchase patterns over that time. The expectation is it starts to contribute more as we get into the back part of the year. It really starts to contribute next year, because as you're starting to close in on 50%, that becomes your starting point for 2027, and that starts to get pretty meaningful as you move into the next year. For now, the way I think about it is it's progressing in line, great customer feedback. I think we've really gotten all connections on board. We're looking forward for it continuing to move to that approaching 50% by the end of the year. We're right on track. Our next question comes from the line of Joshua Jennings with TD Cowen. Your line is open. Good evening, guys. Thank you for taking the question. This is Colin on for Josh. I had a quick one on. Curious now that you have seven million-plus covered lives to play with, what is the kind of awareness level among physicians for the reimbursement already in place? Are physicians identifying which patients can already receive reimbursement with the Medicare decision upcoming? Thank you. Thanks, Colin. It was cutting up a bit, so I am going to do my best with the pieces I have heard. I think really what you are getting at is what is the physician awareness of reimbursement? How much more needs to take place in lieu of expansion of coverage? As more kind of knocks down, what are we doing to go about making sure folks are aware of it? I think that is where you are going. The answer is, obviously, we have been working on this for some time. If you think about the sales force, we have various tools that the sales force gets out in front of physicians and really goes through historical claims adjudication by payer to show them in their practice where does coverage exist, where does it not exist, so that more and more physicians can get comfortable that access exists for them. That continues to take place. It takes a little bit of time to continue to make folks aware, especially as we continue to get more coverage, because every time we show up, we are going to show them a better enhancement or a better improvement in coverage. We have to continue to do that. I also would expect us to continue to bring the CONNECT study with us, because obviously that demonstrates the benefit. If any folks were on the fence around, "Hey, well, what is this going to do and how is this going to impact, and will they use it?" I think what we can both show is, one, if they use it, you are going to see these incredible results. Does not matter what medication you are on. We also can then show the coverage ahead of time. There is always work to do around it. Remember, there is hundreds and hundreds of thousands of prescribers out there, saying this is in generalities, everybody is kind of at a different point in their education. That is what the team is doing. If you were to talk to our sales leadership team, that is the one thing I think they are most excited about, is more and more coverage comes kind of the rebuttal of, well, do they have coverage? We can start to show them, especially with these tools, clear line of sight to where their coverage exists today. Where that coverage does not exist today, they certainly have Stelo in the bag. We are talking about CONNECT and what CONNECT can mean for CMS coverage. I think we put all those in front of physicians today. We have to be mindful of obviously letting them know that the CMS coverage does not exist today. If you prescribe it today, you're going to get a non-coverage. I think seeding that is exactly what we're doing, and we have all the tools to do so. Again, even when there's not coverage, Stelo's a great opportunity there. Hope that helps. Hope that answers the question. If it doesn't, we can always catch up later. Appreciate it. Our next question comes from the line of Jayson Bedford with Raymond James. Your line is open. Good afternoon, congrats on the progress. Just a clarification and then a question. I missed the comments around NCS adds. Was the takeaway that 2Q ads were similar to 1Q? Then my question is really, it's tough not to notice the OpEx leverage. Is there either a timing dynamic at play here, or is this the level in which you can kind of leverage the business going forward? Thanks. Sure. Jayson, yeah. Basically what we're saying is Q2 is in line with Q1. Q1 was a record globally, Q2 is in line with a record globally. We're still waiting for some final patient data to come in. We are also saying that U.S. is in line with a record globally. We're waiting for some final patient data to come in, usually in the U.S., it takes up to 45 days to get it all. What's most important is we do know that U.S. new patients sequentially increased from Q1. This means the OUS patients came down a bit, these things happen with tenders, timing, all of that. Hopefully that gives you some context, essentially in line with a record in the U.S., in line with a record globally. Hopefully that's helpful. To your question on operating leverage, you're right. We've had some operating leverage really ahead of plan, and that's why we've increased the guide on the year. Certainly passing that through. I think over time, the operating leverage that you're seeing and all the work that we've put in place between technology and capability, et cetera, we do expect that to continue to contribute over time. The one thing I will say is for this year, and I think you guys you know this quite well, Jayson, is as we launch our Ireland factory, what do you do in the quarter ahead of starting manufacturing? That's when you hire all the manufacturing folks. We will be doing quite a bit of hiring in Ireland here into the third quarter and before turning on those lines, and those folks are not producing. They're training. They're starting things. Because of that, we'll start some depreciation as well. While we have invested in Ireland into the second quarter, we are going to make some more investments in the third quarter. The good news underneath it all, and I think this is kind of what you're alluding to, Jayson, is the levers we're building in the organization to achieve operating leverage, they continue. I think we're really proud of that thus far. Hopefully that gives you some context. I'm really happy to see it this quarter, really proud of it and glad to pass it along via guidance raises on op margin. Our next question comes from the line of Marie Thibault with BTIG. Your line is open. Hi, good afternoon. Thank you for taking the question. Wanted to ask about international. You had really strong organic growth over there again this quarter. I think the comps may be getting a little bit tougher in the second half. Just want to understand what pace is sustainable. I know Japan went direct. I believe you mentioned Health Canada and the Dexcom G7 15-day approval there. What are some of the catalysts to help drive international growth through the second half of the year? Thanks. Thanks, Marie. The exciting thing about that is the international market is just the tremendous opportunity we have as coverage expands. To take a step back and think about it, we're still working through IIT coverage in a number of our top 10 OUS markets. That's before we even get to basal, and then ultimately NIT. If you look at those populations, just in that core market, we're well north of 60 million potential lives that we could impact. As we think about the second half of the year, you're right, the comps get a little tougher because we had some great access wins in the back half of last year. We continue to get access wins, though, new tenders. When you think about that landscape, much of that is around people having access to Dexcom CGM for the first time because we now have our product portfolio where we can bring Dexcom ONE+ or Dexcom Flex to patient populations that didn't have a choice before. As we do that and we win those tenders and we get on there, it gives them access and we are seeing those wins, and we continue to expect more of those to come. That, as Jereme mentioned, sometimes when you see new patient numbers go up or down, but in the long run, we see a pretty significant opportunity here. To your question on what to think about for the back half of the year in comps, you're all right. The Q3, Q4 comps last year, especially Q3, got a little bit tougher in the international business. We've been talking about that all year though, and so we had talked about where they get a little bit easier in the U.S. and only a little bit tougher in OUS. It's not too much, but nevertheless, it's something to be mindful of. It's always that funny currency thing. At $ 1.17, $1.18 in the euro, I think that's where about breakeven sits. As of June 30th when we're thinking about it, $ 1.14. Just being mindful of that as we think about it. If you neutralize that out, organic growth isn't as impacted, we always want to just be mindful that you have those updated currency assumptions in your model. Our next question comes from the line of Jeff Johnson with Baird. Your line is open. Thank you. Good afternoon, guys. Just want to swing back maybe to the U.S. market. Could you provide any kind of maybe high level color at least on what the drivers of getting back to that kind of equivalent to a record new start in the U.S.? Are we seeing more basal-only patients coming in still? I think we're past the three-year anniversary at this point. Is it really basal only doing most of the heavy lifting? Is it share gains in basal only? My gut would tell me that maybe your T1 and IIT, T2 new starts on a year-over-year basis are down a little bit. I don't know if you'd want to comment on that, but just given those penetration rates. Just kind of the mix and makeup of what drove that good U.S. number this quarter. Thanks. Sure. Yeah, I can cover that. When we talk about kind of a broad based performance, we did see some step up actually from last quarter, even in T1 a little bit. You really saw a little bit of a step up across the board, across T1 and T2 intensive, basal as well, and a little bit there in the type 2 non-insulin. It's a little bit across the board. I think a lot of it is a couple fold and as we think about feedback. Jake alluded to it earlier, the NPS scores continue to go up. This is our third consecutive quarter seeing those go up. When you have a new product in hand, like Dexcom G7 15-day, and we believe that the algorithm, the wear time, the performance in the field, certainly addressing some of the sensor deployment challenges we face. All that, as that plays into happy customers, combined with the coverage levels that we have, and we continue to fight for coverage in the U.S., even eliminating things like prior authorizations, et cetera, to make it easier for folks. I think we're really giving both physicians and customers reasons to come to our product. There's no magic here. We really focus on how to make the customer's life easier, like easier onboarding. Those things go in. Sometimes we don't necessarily talk about it, but you're seeing more and more easier onboarding. You're certainly seeing, obviously, sensor out of the box. Certainly, we expect those to go well. The algorithmic improvements, you don't necessarily always talk about those, but word of mouth is important there. A lot of folks really enjoy the extended wear time. It really has been something we've really seen quite a bit of good feedback on. I think as you build that ecosystem, and obviously there's more and more changes to come as we've talked about the product, we've just really seen a lot of interest there. I wouldn't say there's one silver bullet, but the more and more we work on all of those, plus the more we knock down that reimbursement door and make sure folks are aware they have reimbursement, that's really what we've seen over the course of this quarter. Our next question comes from the line of Joanne Wuensch with Citi. Your line is open. Good evening, and thank you for taking the questions. Briefly, I wanted to make sure that the G8 sensor timeline was still intact, or if you had an update on that. It looks like you acquired Nutrisense in early June. I am just curious what your thoughts are on that and if it is in guidance. Thank you. Yeah. Thanks, Joanne. G8 timeline is still very much intact. The team is doing great work there. We're in the middle of doing lots of validations on the product as we prepare to start some very large clinical trials to show the performance levels of this product. Again, as we mentioned at Investor Day, we expect a step change improvement in accuracy and reliability for this product based on brand-new technology that's being implemented into the G8 system for the very first time. It's also a wearable that's half the size of the G7. Slimmer in terms of height off the body as well as footprint. Again, just continuing to make the technology easy to use, fit into the patient's lifestyle. Very much on track for that. End of 2027, early 2028, just depending on regulatory timing. Yeah, very much on track. It is also a multi-analyte platform. We'll be launching with the glucose version at first, but multi-analyte to come after that as we continue to push towards ketones, potassium, as well as others analytes. We feel that they're an important part of the future for diabetes care and metabolic health. On the Nutrisense point, yes, we acquired Nutrisense. They've been a partner of ours for a long time. We really believe that that technology, when you look at the engagement it drives and the insights that can be derived from the work that they've done, they basically built a system that was CGM-guided nutrition insights and coaching. It was based on professional metabolic health coaches and nutritionists that could basically guide CGM patients. One of the exciting things there is they have lots and lots of history of doing that. As we look at that amount of data and the amount of insights that they've been able to provide over time and the outcomes that they drove with it, we felt like that's something that should be part of the Stelo and G7 and basically our entire product portfolio. We'll be continuing to integrate that technology and advance it with the team, with Nutrisense, to really further the insights that our products provide and drive really significant outcomes. When you think about just metabolic health in general, such a big part of that is the nutrition component. You've seen us continue to expand our product, the ability to capture nutrition. The new Stelo app now analyzes nutrition and gives you a full breakdown of the meal, whether you barcode scanned it, so packaged food, or you took a picture of something that was prepared. That's the type of technology that can really help power this. Yeah. Joanne, to your question on guidance, a big chunk of the revenue that's in Nutrisense is actually CGM pass-through revenue, and it's predominantly Stelo. There's no real change there, right? We've always sold it and passed it through. That's there. The piece that you're referring to is what incremental revenues. I would say this, I allude to a bit earlier, the revenues that are non-CGM related, less than millions you can count on my hand. It's really not a huge revenue item. It's quite small relative to at least the size of Dexcom. What's big is the technology and the technology capabilities, and that's ultimately why we did it. The OpEx has been assumed into it as just typical run rate. We were able to raise the guidance in terms of operating margin performance and assume those costs in over the quarter. Hopefully, that gives you some context. Sometimes, to give you a feel for what the commitment in terms of dollars, et cetera, you'll see it come out in the 10-Q. We didn't publicly disclose it, but in the Q, you'll see in the cash flows what the cash commitment was in terms of purchase price. Our next question comes from the line of Anthony Petrone with Mizuho. Your line is open. Great. Congrats here on a nice print. A couple on type 2 non-insulin intensive. We're hearing from some docs in the field there that potentially the coverage decision could have some requirements around it, specifically around A1C verification at various increments, let's say three, six months, nine months. What do you think coverage could potentially look like? Will it have certain verification requirements to keep folks on CGM in this patient category? Then in the study, it had a 97% utilization rate of CGM, very, very high. When we get to real world, what do you think the utilization intensity for the type 2 non-insulin intensive patients could look like? Thanks, and congrats again. Thanks for the question. Absolutely. Well, just starting with the utilization first. We have our real world registry, we also in that data set see very high utilization. Not quite at 97%, but well above 80% in this population. I think that speaks to For those that have coverage today in the commercial space for the product, the utilization, low out-of-pocket cost in that environment, their utilization is really quite high. To your question around A1C, that's not consistent at all with what we hear in our discussions. If you look at the way CGM benefits users, whether they have a low A1C or a high A1C, the benefits are for everybody, right? Those with higher A1Cs do see larger improvements. For the whole cohort, you see the improvement. When you think about the ADA standards of care. The focus is 7% A1C. That's the target goal. Many people who aren't using CGM are not achieving that. We feel that the CONNECT study is actually going to continue to evolve those standards of care even more than we've seen in the past, so that all people with diabetes are recommended to use a CGM. The other thing to think about too is if there was some sort of A1C kind of threshold, which would first off be inconsistent with what CMS has done in the past, it would also be quite inconsistent with what's already out there with the commercial coverage, which is very broad. It's for anyone who's diagnosed with diabetes. I think it would be quite inconsistent with that and create other issues. The type of idea is not consistent with our discussions that we've been having with CMS and others out there. Our next question comes from the line of Mike Polark with Wolfe Research. Your line is open. Good afternoon. Jake, at the beginning of your prepared remarks, you noted product performance was excellent in the quarter. I heard Jereme allude to some manufacturing and quality stuff in response to one of the prior questions. I'm hoping you can just unpack excellent product performance a little bit more for us. Maybe give us some metrics, scrap, warranty rates, returns, complaints. Obviously, this was a challenge last year. You're rolling out a new product, so it's good to hear things are good. I would love any further color on that mention. Thank you. No, thanks for the question. We did see excellent product performance and one of the biggest measures there is NPS, which is why I mentioned that. The NPS that we're seeing on the G7 product has continued to increase the last three quarters in a row. You're right, we had some challenges last year, particularly in the out-of-box failure rates that disrupted things. Patients got upset. It was not a great experience. We've addressed all of that. The team worked really hard across the board to make sure that we could do that and solve those problems. It really comes down to, as we continue to advance the technology, our focus is always on building the absolute best customer experience, whether it's in the product or in their experience with our customer support. We have seen complaint levels come down because of the enhancements that we've been making. I think if you just look across the board, the product's performing fantastic. We're going to continue to advance it, and we're going to continue to improve that performance. Our job there is never done. If you think about the evolution of CGM over the past 25 years, the products have just gotten better and more reliable, but there's still room to go. As we mentioned with our G8 product, we're very excited about what it's going to bring in terms of performance to this population that could benefit. It's really everybody, whether you have diabetes or not, accurate, reliable glucose data is so critical, even if you're running an AID system. Product performance has been excellent. We're going to continue to build on that as we launch Dexcom G7 15-day around the globe. I know sometimes you've asked the question about, "Well, how do I see it?" Certainly, the NPS scores is a good way. The other way to look at it's one that's kind of a little bit easier to see, even though it's not clear directly, is you look at the margin performance, right? Because some of the things that were impacting margin were freight. Some of that was related to doing the work around product and getting it there. Then, obviously, some of that's related to scrap. As you've seen, that improved pretty steadily as we moved from Q2 last year into Q3, then again into Q4, obviously, then into this year. That improvement in performance is a lot of the work that that team was doing, as Jake alluded to, working real hard over the back half of last year and then into this year. The best proof point is to also look at the results and see that improvement. That is a result of a reduction of, one of the significant ones, the reduction of scrap, which is focusing on quality as it runs through our lines. Our next question comes from the line of Jonathan Block with Stifel. Your line is open. Great. Thanks, guys. Good afternoon. Jereme, maybe just on the financials. You had the gross margin raise of 50 basis points. Is that a function of a different price of oil assumption, call it relative to three months ago, or is that more underlying efficiency that you're seeing and you still have some cushion on oil prices built into the guidance? Maybe just a second part, but still the same question. Based on the guidance, it seems like the 2H implied gross margin is in line with what you saw in 1H. But you do have a growing percentage contribution from the Dexcom G7 15-day you called out. What prevents further GM expansion from the Dexcom G7 15-day tailwind? Is it Ireland, call it, turning on that negates that tailwind? Thanks, guys. I'm certainly happy to answer those. I'll answer your second question first. You hit it spot on. The expectation was always a peak into Q3 in gross margin that would step down as you turned on Ireland, and that's exactly it. Underlying the performance in terms of just core performance underneath it, you'd expect that to continue to come up, but you do have turning on a factory and therefore the cost of each individual product manufactured when you have a factory just turned on. It goes up significantly. Then that leverages over time. The underlying question I think you're getting at is, "Hey, are you starting to see manufacturing efficiencies? Are you starting to see Dexcom G7 15-day?" We are. It's just I'd say there's a little bit of that turning on Ireland. Back to your first question in terms of then oil. The way it kind of works here is as we've purchased resins during these windows, it takes a little time for the price changes in oil then to flow through into product, then to flow through into our P&L. We'll buy the resins, and it usually takes, just like you see at the pump, it takes a little bit of time for that to flow through. I'd say gasoline is much quicker than the flow through on resins. We've bought those. We've made that product. That product gets put on the balance sheet, then it comes through in future periods. You've seen some of it play through here in the second quarter. You'll see still a little bit some of that play through here in the third quarter as we've purchased, capitalized, put it onto the balance sheet, amortized through. I think basically what you'd expect to see is the guidance we gave you last quarter about preparing for some of that headwind associated with the oil prices. About in line with expectations. The raise is really on underlying performance improvements on our lines, throughputs, et cetera, based on work we've done over the first couple of quarters. Our next question comes from the line of Issie Kirby with Redburn. Your line is open. Hey, guys. Thanks for taking my question. I wanted to ask about the Stelo app redesign. Any feedback on that around engagement with the app? You also mentioned bringing some of these features over to the G7 app eventually. Which features are you going to be looking at integrating? Just wondering how you're thinking about app design, particularly as you go after this type 2 non-insulin population. Thanks. Yeah. Thanks for the question. The new app for Stelo has been really well received by users. A lot of our redesign of the app, both the functionality as well as just the design aesthetic, was based on user feedback that we've collected as Stelo's been out for over a year. You look at reviews, you look at customer direct feedback, and we've got a lot of people using the product. You take all that feedback in, so that's really what we built that new app on. It is a completely new ground-up rebuild for us, and so it is going to become our platform for future apps. The question around moving those features to G7, it's actually more this concept of moving G7 to Stelo. A lot of the functionality there, it's beneficial for all users, the nutrition, the coaching. Obviously, there's some different kind of aspects to it when you think about the alert system that G7 requires, right? Stelo doesn't have that. A big part of what G7 does is the protective features, the predictive alerts, the connectivity with automated insulin delivery, the share follow system. We'll basically be bringing that onto the Stelo platform app for those G7 users. I think one of the exciting things here is that there is a lot of overlap with the user needs in these populations. We're using Stelo as kind of the tip of the spear for innovation. With the reception we're seeing from it really hits the mark in terms of advancing it. One of the things I'm really excited about is people who tried Stelo maybe in the past and didn't get the insights that they were after. They didn't see as much value in the real-time data. This new Stelo app brings a lot more contextual insight, and so hopefully that gives them the opportunity to try Stelo again, and see if it meets their needs. I think we're going to see a lot more people that are using it a little more consistently than we saw with the original Stelo version. Our final question comes from the line of Richard Newitter with Truist Securities. Your line is open. Hi, thanks for squeezing me in, and congrats on the quarter. Maybe just one follow-up to John's question earlier on gross margin. You started to get at it, you're obviously seeing improved underlying trends in part related to Dexcom G7 15-day. I guess, when can we expect to see the peak impact from the Dexcom G7 15-day compound? If you're exiting at 50% this year into next, does that mean one of the quarters in 2027, that'll be the final kind of stepped up run rate? I'm just trying to get a sense for when we might feel the max incremental impact of this ongoing tailwind. Thanks. Yeah. It's a good question. I'll kind of point maybe a little bit back to Investor Day, because we try to give some context to the cadence of the rollout. What we're talking about is U.S. 15-day G7. Obviously we expect to exit this year at approaching 50%. If you do an average over the course of the year, you're at 20%, 25%. Obviously next year, if your starting point is approaching 50%, and you go up from there, that's a meaningful step up. Certainly in next year, the step-up's going to be more. The other thing you have to be mindful of is there's a lot of product going on around the world today between Dexcom ONE+ and G7 outside the U.S., where that's also going to start to roll in. It's actually going to be a multi-year improvement as you start to think about sunsetting G6, which is obviously in process now, as more and more folks move off of G7 10-day- 15-day. Then of course, G8 is going to be on a 15-day platform. What I would say is there's not really one quarter where it plateaus. It should be really a steady help. In terms of the U.S., which I think is kind of where your focus is, obviously the biggest improvements are going to really start to accrue into next year, just given the starting point for the year is going to be so much higher. Nevertheless, look, it's all good. I think as we move through, we'll keep you apprised in terms of what that transition looks like. We'll also keep you apprised in terms of our OUS markets and as our OUS markets come on and our Dexcom ONE+ markets come on. I think all those are also really important too, as you're building kind of a global model. Again, easiest way to look at the timelines is go back to the Investor Day. I think you'll see kind of the cadence of when we expect those to hit. The first OUS one, you can see we just got approval in Canada for 15 days. We're going to start knocking those down as well. It's going to be kind of a steady drip, I think, over time, but certainly a positive one. We hope everybody sees the positive quality results that we're seeing here in the U.S. We expect that. That concludes our question and answer session. I would now like to turn the call back over to Mr. Jake Leach for closing remarks. Thank you, operator. As we wrap up today, I would like to take a moment to recognize the people who make Dexcom what it is. Across our company, our employees show up every day with an unwavering commitment to the people we serve. Our results this quarter are a reflection of their passion and commitment to executing on our mission. We're proud of the momentum we've created, we believe we're still really early in the chapters of a much larger opportunity to transform how diabetes and metabolic health are managed around the world. The road ahead is very exciting, we're confident in our strategy, our innovation pipeline, and most importantly, in our people. Thanks, everybody. Ladies and gentlemen, this concludes today's call, we thank you for your participation. You may now disconnect.